OCUL - Ocular Therapeutix Inc
IEX Last Trade
8.82
0.260 2.948%
Share volume: 599,924
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$8.56
0.26
3.04%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-07 | 2023-03-06 | 2023-05-08 | 2023-08-07 | 2023-11-07 | 2024-03-11 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 173.071 M | 158.579 M | 149.289 M | 128.573 M | 122.558 M | 162.384 M | 252.060 M | 538.947 M | |
| Current Assets | 160.322 M | 145.615 M | 129.627 M | 107.162 M | 100.712 M | 141.258 M | 232.235 M | 519.824 M | |
| Inventories | 1.500 M | 1.545 M | 1.974 M | 2.266 M | 2.204 M | 2.257 M | 2.305 M | 2.574 M | |
| Other Current Assets | 3.801 M | 3.318 M | 4.028 M | 4.746 M | 4.593 M | 4.862 M | 7.794 M | 7.666 M | |
| Short Term Investments | 3.801 M | 3.318 M | 4.028 M | 4.746 M | 4.593 M | 4.862 M | 7.794 M | 7.666 M | |
| Total Receivables | 20.482 M | 19.802 M | 21.325 M | 21.124 M | 27.309 M | 23.589 M | 26.179 M | 26.546 M | |
| Current Cash | 134.539 M | 120.950 M | 102.300 M | 79.026 M | 66.606 M | 110.550 M | 195.807 M | 482.888 M | |
| Total Non-current Assets | 12.749 M | 12.964 M | 19.662 M | 21.411 M | 21.846 M | 21.126 M | 19.825 M | 19.123 M | |
| Property Plant Equipment | 6.680 M | 7.196 M | 9.856 M | 12.022 M | 12.830 M | 12.494 M | 11.739 M | 11.450 M | |
| Other Assets | 4.305 M | 4.004 M | 8.042 M | 7.625 M | 7.252 M | 6.868 M | 6.472 M | 6.059 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 173.071 M | 158.579 M | 149.289 M | 128.573 M | 122.558 M | 162.384 M | 252.060 M | 538.947 M | |
| Total liabilities | 107.268 M | 112.350 M | 113.910 M | 118.862 M | 119.471 M | 154.531 M | 160.929 M | 130.964 M | |
| Total current liabilities | 26.113 M | 29.269 M | 31.395 M | 29.715 M | 32.357 M | 35.066 M | 34.896 M | 24.298 M | |
| Accounts Payable | 3.703 M | 5.308 M | 5.123 M | 5.441 M | 3.572 M | 3.984 M | 4.389 M | 6.453 M | |
| Other liabilities | 23.461 M | 25.127 M | 19.831 M | 26.354 M | 26.141 M | 38.325 M | 44.230 M | 33.803 M | |
| Current long term debt | 1.771 M | 1.744 M | 1.599 M | 1.818 M | 3.796 M | 1.878 M | 1.586 M | 1.542 M | |
| Long term debt | 57.694 M | 57.954 M | 62.684 M | 62.793 M | 60.973 M | 81.140 M | 81.803 M | 72.863 M | |
| Other liabilities | 23.461 M | 25.127 M | 19.831 M | 26.354 M | 26.141 M | 38.325 M | 44.230 M | 33.803 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 65.803 M | 46.229 M | 35.379 M | 9.711 M | 3.087 M | 7.853 M | 91.131 M | 407.983 M | |
| Common stock | 76.764 M | 76.976 M | 77.014 M | 77.386 M | 78.048 M | 79.373 M | 84.502 M | 132.022 M | |
| Retained earnings | -577.112 M | -601.300 M | -616.842 M | -647.160 M | -667.842 M | -668.358 M | -697.578 M | -762.426 M |